Please turn JavaScript on
Find more feeds
European Biotechnology Magazine icon

European Biotechnology Magazine

Subscribe to European Biotechnology Magazine’s news feed.

Click on “Follow” and decide if you want to get news from European Biotechnology Magazine via RSS, as email newsletter, via mobile or on your personal news page.

Subscription to European Biotechnology Magazine comes without risk as you can unsubscribe instantly at any time.

You can also filter the feed to your needs via topics and keywords so that you only receive the news from European Biotechnology Magazine which you are really interested in. Click on the blue “Filter” button below to get started.

Website title: European Biotechnology Magazine

Is this your feed? Claim it!

Publisher:  Unclaimed!
Message frequency:  1.24 / day

Message History

SERB to pay Hansa €110M upfront for EU rights to kidney transplant drug

SERB Pharmaceuticals has agreed to pay Hansa Biopharma €110 million upfront for European rights to a conditionally approved kidney transplant drug.

The post SERB to pay Hansa €110M upfront for EU r...


Read full story
New CCO starts in June

Marc Clausse will take up his new role as Chief Commercial Officer at Santhera Pharmaceuticals (SIX: SANN) at the beginning of June. He succeeds Geert Jan van Daal, who is retiring.

The post New CCO starts in June appeared first on


Read full story
Harbour posts preclinical data on would-be rival to Eli Lilly’s $1.9B obesity bet

Harbour BioMed has published preclinical obesity data on a potential challenger to Eli Lilly’s bimagrumab discovered using its artificial intelligence-enabled platform.

The post Harbour pos...


Read full story
Co-founder and CEO steps down

Dr Andrea Pfeifer, long-serving CEO and co-founder from AC Immune, has decided to retire. AC Immune’s Board of Directors has appointed the Chair, Dr Martin Zügel, to serve as interim CEO while the ongoing search for a permanent successor continues.

The post


Read full story
Millions for Preclinical Immunology: Boehringer Teams Up with Immunitas

German Boehringer Ingelheim is doubling down on next-generation autoimmune therapies with a deal worth up to €407.5m for a preclinical Immunitas (USA) antibody programme. The agreement highlights the growing race for selective immune-cell depletion approaches — and adds another strategic win for Novartis-, Merck-, Bayer- and Evotec-backed Immunitas.

The post


Read full story